EUVIMEDEUVIMED entdecken
Crossref

Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

Alexandra C Hristov, Trilokraj Tejasvi, Ryan A Wilcox iD

American Journal of Hematology · 2023-08 · 98 (8) · 1326-1332

DOI: 10.1002/ajh.26968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 22.05.2023. Verfasst von Alexandra C Hristov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Skin Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Approximately one‐fourth of primary cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement. Risk‐Stratification Disease histopathology remains the most important prognostic determinant in primary cutaneous B‐cell lymphomas. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis. Risk‐Adapted Therapy PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Non-HodgkinSkin NeoplasmsHumansB-LymphocytesBiopsyRituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, Michigan, USA.

ORCID-Profile: Ryan A Wilcox

Förderung

  • NCI NIH HHS

Zitieren

APA

Hristov, A. C., Tejasvi, T., & Wilcox, R. A. (2023). Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98(8), 1326-1332. https://doi.org/10.1002/ajh.26968

Vancouver

Hristov AC, Tejasvi T, Wilcox RA. Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology. 2023;98(8):1326-1332. doi:10.1002/ajh.26968

BibTeX
@article{Hristov2023,
  author = {Hristov, Alexandra C and Tejasvi, Trilokraj and Wilcox, Ryan A},
  title = {Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {8},
  pages = {1326--1332},
  doi = {10.1002/ajh.26968}
}
Kostenlos starten →